Treatment Resistant Depression - CPL | US
Offer Details: | |
|---|---|
| Offer Name: | Treatment Resistant Depression - CPL | US |
| Payout: | $45.00 / CPA |
| Preview: | Preview Landing Page |
| Categories: | Ecommerce |
| Network: | DYNU IN MEDIA |
| Last Updated: | Apr 25, 2025 |
| Countries: | US |
Ages: 18+
Gender: All
Study Description:
The purpose of this study is to see whether an investigational drug can be used to treat depression that has not responded to other antidepressant therapies. Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone has taken, or is currently taking, two or more antidepressants that are not working, this is sometimes referred to as treatment-resistant depression or TRD. The investigational drug in this study is a synthetic (man-made) form of psilocybin, also known as 'magic mushrooms'. The use of this study drug is legal for research purposes. You may qualify to participate if you are currently experiencing a depressive episode that is not being helped with medication. If enrolled, you will be randomly selected to receive one of 3 doses of the investigational study drug with the support of a specially trained therapist. The dosing session will last approximately 6 to 8 hours and will be video, and audio recorded. You will be required to attend several screening visits to determine your eligibility for the study. Your total participation in the study will last up to approximately 1 year with multiple follow-up appointments after your dosing session. Please note, some of the visits during the study can be conducted remotely. There are up to two re-treatment opportunities throughout the study. One is an open label period of the study where you are guaranteed to receive the highest dose of the investigational study drug, if you are eligible. Study assessments will include collections of blood and urine samples, physical exams, and questionnaires on your experience and mental health. The research site conducting the study will be able to provide you with more information about the requirements for enrollment. Reimbursement for reasonable, out-of-pocket expenses and travel may be available to qualified individuals.
Top DQs:
- Current depression episode of depression has lasted 6 months +
- Must have tried two or more anti-depressant medications to treat this current episode of depression
- Cannot also be diagnosed with schizophrenia, schizoaffective disorder/Schizophreniform Disorder, Bipolar Disorder, or Borderline Personality Disorder
Proof required for approval
Gender: All
Study Description:
The purpose of this study is to see whether an investigational drug can be used to treat depression that has not responded to other antidepressant therapies. Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone has taken, or is currently taking, two or more antidepressants that are not working, this is sometimes referred to as treatment-resistant depression or TRD. The investigational drug in this study is a synthetic (man-made) form of psilocybin, also known as 'magic mushrooms'. The use of this study drug is legal for research purposes. You may qualify to participate if you are currently experiencing a depressive episode that is not being helped with medication. If enrolled, you will be randomly selected to receive one of 3 doses of the investigational study drug with the support of a specially trained therapist. The dosing session will last approximately 6 to 8 hours and will be video, and audio recorded. You will be required to attend several screening visits to determine your eligibility for the study. Your total participation in the study will last up to approximately 1 year with multiple follow-up appointments after your dosing session. Please note, some of the visits during the study can be conducted remotely. There are up to two re-treatment opportunities throughout the study. One is an open label period of the study where you are guaranteed to receive the highest dose of the investigational study drug, if you are eligible. Study assessments will include collections of blood and urine samples, physical exams, and questionnaires on your experience and mental health. The research site conducting the study will be able to provide you with more information about the requirements for enrollment. Reimbursement for reasonable, out-of-pocket expenses and travel may be available to qualified individuals.
Top DQs:
- Current depression episode of depression has lasted 6 months +
- Must have tried two or more anti-depressant medications to treat this current episode of depression
- Cannot also be diagnosed with schizophrenia, schizoaffective disorder/Schizophreniform Disorder, Bipolar Disorder, or Borderline Personality Disorder
Proof required for approval
DYNU IN MEDIA
DYNU IN MEDIA is a super match CPA/CPL network for earning money online that provides you with all techniques allowing you to monetize your traffic in all channels. We guarantee outstanding support to our publishers. Our devoted team with experience in the affiliate marketing industry will give you full-assist, direct offers in a wide-ranging variety of verticals and top GEOs, and a flexible payment schedule of NET15 & NET30. Hitting more than 20,000 leads generated daily for over 200 influential clients, along with an increasing number of HQ publishers to 300 and more, DYNU IN MEDIA is taking high pride in our professionalism and high integrity.
